Alaunos Therapeutics, Inc.
TCRT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -50% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -53,650% | -18,550% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -53,650% | -18,550% |
| EPS Diluted | -0.55 | -0.63 | -0.67 | -0.46 |
| % Growth | 12.7% | 6% | -45.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |